Literature DB >> 2299103

Leukotriene C4 elimination and metabolism in man.

N H Maltby1, G W Taylor, J M Ritter, K Moore, R W Fuller, C T Dollery.   

Abstract

Three doses of radiolabeled leukotriene C4 (0.2 to 15 muCi) were infused into three subjects to investigate its metabolism and routes of elimination during 4 days. Between 12% and 20% of the infused dose was recovered in the urine within 24 hours, of which a substantial and relatively constant proportion (4.1% to 6.3% total dose) appeared as leukotriene E4 (LTE4), mainly in the first 4 hours. Polar omega-oxidation products, N-acetyl LTE4, and tritiated water were also present. Fecal elimination accounted for a further 30% to 40% of the infused dose. In the absence of altered metabolism or biliary excretion, urinary LTE4 may be a useful measure of whole body production of the cysteinyl leukotrienes.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2299103     DOI: 10.1016/0091-6749(90)90214-o

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  12 in total

Review 1.  The measurement of leukotrienes in human fluids.

Authors:  J Y Westcott
Journal:  Clin Rev Allergy Immunol       Date:  1999 Spring-Summer       Impact factor: 8.667

Review 2.  Cysteinyl leukotrienes in asthma: current state of therapeutic evaluation.

Authors:  I K Taylor
Journal:  Thorax       Date:  1995-09       Impact factor: 9.139

3.  Leukotrienes and aspirin induced asthma.

Authors:  T H Lee; P E Christie
Journal:  Thorax       Date:  1993-12       Impact factor: 9.139

4.  Pharmacokinetic and pharmacodynamic analysis of a novel leukotriene biosynthesis inhibitor, MK-0591, in healthy volunteers.

Authors:  T Uematsu; M Kanamaru; K Kosuge; K Hara; N Uchiyama; N Takenaga; W Tanaka; B S Friedman; M Nakashima
Journal:  Br J Clin Pharmacol       Date:  1995-07       Impact factor: 4.335

5.  Assessment of the in vivo biochemical efficacy of orally active leukotriene biosynthesis inhibitors.

Authors:  P Tagari; C Brideau; C Chan; R Frenette; C Black; A Ford-Hutchinson
Journal:  Agents Actions       Date:  1993-09

6.  Impaired degradation of leukotrienes in patients with peroxisome deficiency disorders.

Authors:  E Mayatepek; W D Lehmann; J Fauler; D Tsikas; J C Frölich; R B Schutgens; R J Wanders; D Keppler
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808

7.  Effect of the leukotriene receptor antagonists FPL 55712, LY 163443, and MK-571 on the elimination of cysteinyl leukotrienes in the rat.

Authors:  C Denzlinger; M Grimberg; A Kapp; C Haberl; W Wilmanns
Journal:  Br J Pharmacol       Date:  1991-04       Impact factor: 8.739

8.  Effects of leukotrienes C4 and D4 on human isolated saphenous veins.

Authors:  S P Allen; A H Chester; P J Piper; A P Sampson; E S Akl; M H Yacoub
Journal:  Br J Clin Pharmacol       Date:  1992-11       Impact factor: 4.335

9.  Negative ion tandem mass spectrometry of leukotriene E4, and LTE 4, metabolites: Identification of LTE 4, in human urine.

Authors:  A Sala; K Kayganich; J A Zirrolli; R C Murphy
Journal:  J Am Soc Mass Spectrom       Date:  1991-08       Impact factor: 3.109

10.  Persistent increase in plasma and urinary leukotrienes after acute asthma.

Authors:  A P Sampson; D P Castling; C P Green; J F Price
Journal:  Arch Dis Child       Date:  1995-09       Impact factor: 3.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.